Ballpoint pen lying on medical prescription near phonendoscope in doctors office. Illegal prescription of drugs concept

Drug policy 101: Kaiser Permanente’s approach to pharmaceutical detailing

As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is critical for policymakers to understand the potential solutions.

This brief describes Kaiser Permanente’s approach to providing high-quality, unbiased information to prescribers.

Drug Policy 101: Kaiser Permanente’s Approach to Drug Detailing

Watch Dr. Maisha Draves, MD, MPH, Medical Director of Pharmacy, describe Kaiser Permanente’s approach

Other papers in this series
Drug policy 101: Kaiser Permanente’s approach to pharmaceutical detailing
Drug policy 101: Pharmaceutical marketing tactics
Drug policy 101: Breaking down different types of drug products
Drug policy 101: The state of the pharmaceutical evidence base
Drug policy 101: Drug patents
Drug policy 101: Biosimilars
Drug policy 101: FDA risk evaluation and mitigation strategy (REMS)
Drug Policy 101: Pay-for-delay
Back To Top